A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo1 study

AIDS

Volumn 14, Issue 9, 2000, Pages 1171-1180

  Carr, Andrew ^a   Chuah, John ^e   Hudson, Jeff ^b   French, Martyn ^c   Hoy, Jennifer ^d   Law, Matthew ^b   Sayer, David ^c   Emery, Scan ^b   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e NONE

Author keywords

Adherence; Combination therapy; HIV; Virological failure

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUSTRALIA; CD4 LYMPHOCYTE COUNT; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; STAVUDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 0033933688     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00014     Document Type: Article

References (26)

1. 1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. 2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA panel. JAMA 1998, 280:78-86.
3. 3. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998, 280:35-41.
4. 4. Foudraine NA, de Jong JJ, Jan Weverling G, et al. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998, 12:1513-1519.
5. 5. Raffi F, Reliquet V, Auger S, et al. Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral-experienced patients. AIDS 1998, 12:1999-2005.
6. 6. Kirk O, Katzenstein TL, Gerstoft J, et al. Combination therapy containing ritonavir plus saquinavir has superior short-term antiretroviral efficacy: a randomized trial. AIDS 1999, 13: F9-16.
7. 7. The AVANTI Steering Committee. Analysis of HIV-1 clinical trials: statistical magic? Lancet 1999, 353:2061-2064.
8. 8. Staszewski S, DeMasi R, Hill A, Dawson D. HIV-1 RNA, CD4 count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998, 12:1-6.
9. 9. AVANTI study group. AVANTI-2: randomised, double blind, trial to evaluate the efficacy and safety of zidovudine + lamivudine versus zidovudine + lamivudine + indinavir in HIV-infected antiretroviral-naive patients. AIDS 2000, 14:367-374.
10. 10. Mitsuyasu T, Skolnik PR, Cohen SR, et al. Activity of the soft gelatin formulation of saquinvair in combination therapy in antiretroviral-naive patients. AIDS 1998, 12:F103-109.
11. 11. Cohen Stuart JWT, Schuurman R, Burger DM, et al. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study). AIDS 1999, 13: F53-58.
12. 12. Staszewski S, Morales-Ramiez J, Tashima, KT, et al. Efavirenz + zidovudine + lamivudine, efavirenz + indinavir, and indinavir + zidovudine + lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1873.
13. 13. Montaner JSG, Reiss P, Cooper DA, et al. A randomised double-blind trial comparing combinations of nevirapine, didanosine and zidovudine for HIV-infected persons: the INCAS trial. JAMA 1998, 279:930-937.
14. 14. Mobley JE, Pollard RB, Schrader S, et al. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AIDS 1999, 13:F87-93.
15. 15. Kind P, Dolan P, Gudex C, Williams A, et al. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998, 316:736-741.
16. 16. French MAH, Cameron PU, Grimsley G, Smyth LA, Dawkins RL. Correction of human immunodeficiency virus-associated depression of delayed-type hypersensitivity (DTH) after zidovudine therapy: DTH, CD4 + T-cell numbers and epidermal Langerhans cell density are independent variables. Clin Immunol Immunopathol 1990, 55:86-96.
17. 17. Erali M, Hillyard DR. Evaluation of the ultrasensitive Roche Amplicor HIV-1 Monitor assay for quantitation of human immunodeficiency virus type 1 RNA. J Clin Micro 1999, 37:792-795.
18. 18. Kaufmann GR, Duncombe C, Cunningham P, et al. Treatment response and durability of dual protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1 infected patients. AIDS 1998, 12:1625-1630.
19. 19. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999, 13:F35-44.
20. 20. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
21. 21. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
22. 22. Carr A, Miller J, Law L, Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-32.
23. 23. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of lipodystrophy in patients receiving a stable nucleoside-analogue therapy. AIDS 1999 13:1659-1668.
24. 24. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance geno-typing in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195-2199.
25. 25. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-1098.
26. 26. Piketty C, Castiel P, Belec L, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998, 12:745-750.